Kenya Launches Third Phase of Groundbreaking TB Vaccine Trial

Kenya has launched the third phase of a clinical trial for the M72/AS01E tuberculosis (TB) vaccine candidate, becoming the second African nation to undertake this initiative after South Africa. This trial, which began earlier this month, aims to assess the efficacy and safety of a vaccine that could potentially prevent pulmonary TB in adolescents and adults—the most prevalent form of the disease. The Phase 3 clinical trial, announced by the Bill & Melinda Gates Medical Research Institute (Gates MRI) in March, commenced with the enrollment of participants on July 12 in va...